EZH2 and small cell lung carcinoma: In addition to enhancing drug efficacy, identifying specific patients likely to respond well is crucial, which could be addressed by our finding that SCLC patients with CRACDlow tumors may benefit from combining EZH2 inhibitors and immunotherapy.